Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 02 Oct 2024 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Results (n=33) presented at the 114th Annual Meeting of the American Association for Cancer Research
- 01 Feb 2023 Status changed from recruiting to active, no longer recruiting.